TD Cowen Elevates Johnson & Johnson's Price Target Following Robust Q4 Performance
TD Cowen has increased its price target for Johnson & Johnson to $250, citing impressive fourth-quarter revenue and promising guidance for 2026. Other financial institutions also upgraded their outlooks based on the company's solid sales and earnings results, reflecting positive sentiment toward the healthcare company's sustained growth.